A fusion protein that ferries a healthy version of a bone-related enzyme gone awry has shown early clinical success in treating a rare bone disorder with no known therapy, researchers reported earlier this month at the Endocrine Society's linkurl:annual meeting;http://www.endo-society.org/endo/ in Washington, DC. The drug -- which is essentially a protein-based enzyme delivery mechanism -- could open the door to treatments of other skeletal disorders that have so far been deemed untreatable.
Radiographic signs of childhood (left)
and adult (right) hypophosphatasia

Image: NIH
"This is probably the most promising approach so far" for metabolic bone disorder therapies, linkurl:Sundeep Khosla,;http://mayoresearch.mayo.edu/staff/khosla_s.cfm an endocrinologist at the Mayo Clinic in Rochester, Minn., who was not affiliated with the work, told __The Scientist__. The new therapy targets a rickets-like disease called linkurl:hypophosphatasia;http://ghr.nlm.nih.gov/condition=hypophosphatasia (HPP), which is caused by a single mutation in the gene coding for an enzyme known as tissue non-specific alkaline phosphatase, or TNSALP....

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?